GET DAILY SIGNALSZevra Therapeutics (ZVRA) Delivers +45% Revenue Growth in Q3 2026
Key Takeaways
- Zevra reported third-quarter 2026 net revenue of $37.8 million, up 45% from $26.1 million in the same period last year.
- Lead product MIPLYFFA, used to treat Niemann-Pick disease type C (NPC), generated $34.0 million in net U.S. revenue.
- Diluted earnings per share (EPS) of $0.26 topped consensus estimates of roughly $0.14–$0.16, while revenue also beat expectations near $37.1 million.
- The company ended the quarter with $270.9 million in cash, cash equivalents, and investments, strengthening its runway for pipeline development.
- Total operating expenses rose to $24.1 million, reflecting increased investment in commercialization and R&D.
Earnings Context and Why It Matters
Zevra Therapeutics is a commercial-stage rare-disease company whose investment story centers on the launch progress of MIPLYFFA (arimoclomol), its FDA-approved therapy for NPC, a rare and progressive neurodegenerative disorder. With a small, identifiable patient population, quarterly revenue serves as a clear indicator of commercial execution, prescription uptake, and payer coverage. Earlier quarters showed steady growth, and this report helps confirm whether that momentum is building. For investors, the results also shed light on whether rising operating costs align with top-line expansion and whether the balance sheet supports the celiprolol program along with European regulatory efforts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
Zevra reported third-quarter 2026 net revenue of $37.8 million, a 45% increase from $26.1 million in the year-ago quarter. The result was driven by $34.0 million in net U.S. MIPLYFFA revenue, along with $0.2 million from OLPRUVA (sodium phenylbutyrate) and $3.6 million in net reimbursements from its global Expanded Access Program (EAP).
Net income came in at $19.2 million, or $0.31 per basic and $0.26 per diluted share, compared with a net loss of $0.5 million, or $(0.01) per share, in Q3 2025. The quarter included $5.1 million in non-cash income from fair value adjustments tied to warrant and contingent value rights (CVR) liabilities. GAAP EPS of $0.26 exceeded consensus estimates of about $0.14–$0.16, while revenue also topped the roughly $37.1 million consensus.
Total operating expenses were $24.1 million, up from $20.4 million a year earlier. R&D expense increased to $4.9 million, and selling, general, and administrative (SG&A) expense rose to $19.1 million, reflecting higher commercial and infrastructure costs. Zevra closed the quarter with $270.9 million in cash, cash equivalents, and investments.
How the Market Reacted
Heading into the report, sentiment was cautiously optimistic, with analysts raising EPS estimates in the weeks before the release and the stock trading near $10. After the results, early reports indicated the shares moved higher in after-hours trading, as investors responded to a top-and-bottom-line beat and continued MIPLYFFA momentum. The stock has been volatile in recent months, so traders are likely weighing strong commercial execution against higher operating expenses and the still-pending European regulatory decision for arimoclomol. The key question for the market is whether prescription growth can be sustained while costs remain controlled.
Looking Ahead: Key Factors to Monitor
Several catalysts are likely to shape Zevra's story in the coming quarters. First, investors will watch the trajectory of MIPLYFFA prescription enrollment forms, which reached 197 cumulatively since launch, with 13 new forms added in Q3 2026. Patient retention and expanding payer coverage — currently around 69% — are important signals for future revenue durability.
Second, the company is pursuing European access for arimoclomol through a re-examination of its Marketing Authorisation Application (MAA) by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). An approval could meaningfully expand the product's addressable market.
Third, Zevra anticipates filing a supplemental New Drug Application (sNDA) with the FDA in Q1 2027 to potentially expand MIPLYFFA's label to infants under 24 months of age, following a recent Type B meeting.
Finally, the Phase 3 DiSCOVER trial of celiprolol for Vascular Ehlers-Danlos Syndrome (VEDS) continues enrollment, with 72 patients enrolled and four confirmed events as of quarter-end. With a strong cash position, Zevra has flexibility to advance these priorities, though rising SG&A and R&D costs will remain a key area for investors to monitor.
Using AI Tools in My Research
In my analysis of names like ZVRA, I regularly incorporate Tickeron’s AI Screener to scan for comparable companies and refine ideas based on technical patterns, fundamentals, and performance metrics. It helps surface relevant opportunities more efficiently than manual methods alone, allowing me to cross-check data points and build stronger watchlists without replacing my own judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ZVRA in +10.59% Uptrend, rising for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ZVRA advanced for three days, in 230 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ZVRA's RSI Indicator exited the oversold zone, 18 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ZVRA as a result. In 76 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for ZVRA just turned positive on October 29, 2026. Looking at past instances where ZVRA's MACD turned positive, the stock continued to rise in 40 of 49 cases over the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
ZVRA moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZVRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
ZVRA broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ZVRA entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 29 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. ZVRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 79 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZVRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.873) is normal, around the industry mean (2.788). P/E Ratio (10.969) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (10.667) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (5.176) is also within normal values, averaging (440.869).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology